GSRCX | VSTSX | GSRCX / VSTSX | |
Total Expense Ratio | 1.76 | 0.01 | 17,600% |
Annual Report Gross Expense Ratio | 2.02 | 0.01 | 20,200% |
Fund Existence | 20 years | 9 years | - |
Gain YTD | 5.235 | 9.284 | 56% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000 | 5000000000 | 0% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 437M | 1.91T | 0% |
Annual Yield % from dividends | 0.63 | 1.20 | 53% |
Returns for 1 year | -5.99 | 16.23 | -37% |
Returns for 3 years | -2.78 | 46.90 | -6% |
Returns for 5 years | 23.60 | 85.95 | 27% |
Returns for 10 years | -37.94 | N/A | - |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
IDNA | 22.88 | 0.48 | +2.14% |
iShares Genomics Immnlgy & Hlthcr ETF | |||
GBXC | 25.91 | 0.10 | +0.40% |
Goldman Sachs U.S. Lg Cp Buffr 3 ETF | |||
DDM | 101.25 | 0.26 | +0.26% |
ProShares Ultra Dow30 | |||
IWX | 85.63 | -0.01 | -0.01% |
iShares Russell Top 200 Value ETF | |||
ITDH | 35.74 | N/A | -0.01% |
iShares LifePath Target Date 2060 ETF |